Articles by Cora N. Sternberg, MD
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs.
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options.
The panel discusses studies and areas of interest related to treatment options for advanced bladder cancer.
The panel discussed how treatments used in the metastatic space are moving into the perioperative setting.
The panel discusses the potential for more targeted treatments making their way into the advanced bladder cancer space.
The panel addresses treatment sequencing decisions following disease relapse.
The panel discusses the approach to treating patients with platinum-ineligible bladder cancer.
The panel discusses patient characteristics and treatment sequencing considerations.
The panel discusses the approach to treating patients with cisplatin-ineligible bladder cancer.
The panel discusses the approach to treating patients with cisplatin-eligible bladder cancer.
Dr. Sternberg opines on the importance of mutation status in advanced PC as well as germline and somatic testing.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.